MedTrace Logo

Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

NCT06045299 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-03-03

No results posted yet for this study

Summary

A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia

Conditions

Interventions

DRUG

Aceclidine+Brimonidine combination ophthalmic solution

Aceclidine+Brimonidine combination ophthalmic solution

DRUG

Aceclidine ophthalmic solution

Aceclidine ophthalmic solution

DRUG

Placebo (Vehicle) ophthalmic solution

Placebo (Vehicle) ophthalmic solution

Sponsors & Collaborators

  • LENZ Therapeutics, Inc

    collaborator OTHER

  • Corxel Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Gloria Sun · Corxel Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2024-08-19
Completion
2025-01-27

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06045299 on ClinicalTrials.gov